€186.60
0.97% day before yesterday
Brüssel, Dec 20, 05:37 pm CET
ISIN
BE0003739530
Symbol
UCB
Sector
Industry

UCB Stock price

€186.60
+16.70 9.83% 1M
+49.75 36.35% 6M
+107.70 136.50% YTD
+109.92 143.35% 1Y
+89.66 92.49% 3Y
+114.68 159.45% 5Y
+120.70 183.16% 10Y
Brüssel, Closing price Fri, Dec 20 2024
+1.80 0.97%
ISIN
BE0003739530
Symbol
UCB
Sector
Industry

Key metrics

Market capitalization €35.40b
Enterprise Value €38.01b
P/E (TTM) P/E ratio 147.63
EV/FCF (TTM) EV/FCF 76.64
EV/Sales (TTM) EV/Sales 6.97
P/S ratio (TTM) P/S ratio 6.49
P/B ratio (TTM) P/B ratio 3.95
Dividend yield 0.73%
Last dividend (FY24) €1.36
Revenue growth (TTM) Revenue growth 5.27%
Revenue (TTM) Revenue €5.45b
EBIT (operating result TTM) EBIT €504.00m
Free Cash Flow (TTM) Free Cash Flow €496.00m
EPS (TTM) EPS €1.26
P/E forward 68.31
P/S forward 6.04
EV/Sales forward 6.49
Show more

Is UCB a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,892 stocks worldwide.

UCB Stock Analysis

Unlock Scores for Free

Analyst Opinions

18 Analysts have issued a UCB forecast:

12x Buy
67%
5x Hold
28%
1x Sell
6%

Analyst Opinions

18 Analysts have issued a UCB forecast:

Buy
67%
Hold
28%
Sell
6%

Financial data from UCB

Income Statement P&L | Balance Sheet | Cash Flow


TTM Annually
Jun '24
+/-
%
5,454 5,454
5% 5%
100%
- Direct Costs 1,966 1,966
8% 8%
36%
3,488 3,488
4% 4%
64%
- Selling and Administrative Expenses 630 630
29% 29%
12%
- Research and Development Expense 1,660 1,660
2% 2%
30%
1,198 1,198
3% 3%
22%
- Depreciation and Amortization 694 694
9% 9%
13%
EBIT (Operating Income) EBIT 504 504
16% 16%
9%
Net Profit 240 240
27% 27%
4%

In millions EUR.

Don't miss a Thing! We will send you all news about UCB directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Company Profile

UCB SA engages in the research, development, and commercialization of pharmaceutical and biotechnology products. It offers medicinal products such as briviact, keppra, vimpat, neupro, cimzia, nootropil, xyrem, xyzal, and zyrtec. The company was founded by Emmanuel Janssen on January 18, 1928 and is headquartered in Brussels, Belgium.

Head office Belgium
CEO Jean-Christophe Tellier
Employees 9,083
Founded 1925
Website www.ucb.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today